PGP and cancer: These results highlight the critical role of miR-137 in modifying the cancer cells’ reaction to doxorubicin treatment and underscore miR-137 as an extremely favourable target for reducing CAR-related P-gp protein levels in doxorubicin-resistant neuroblastoma tumour cells (Takwi et al., 2014).